- Home
- CRT vs MCRB Comparison
CRT vs MCRB Comparison
Compare CRT & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CRT | MCRB |
|---|---|---|
| Founded | 1991 | 2010 |
| Country | United States | United States |
| Employees | 2 | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.1M | 48.4M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | CRT | MCRB |
|---|---|---|
| Price | $9.96 | $4.64 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | 14.9K | ★ 71.4K |
| Earning Date | 04-14-2026 | 05-11-2026 |
| Dividend Yield | ★ 5.29% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $789,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.55 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.07 | $4.59 |
| 52 Week High | $11.10 | $29.98 |
Technical Indicators
Market Signals| Indicator | CRT | MCRB |
|---|---|---|
| Relative Strength Index (RSI) | 49.64 | 37.54 |
| Support Level | $9.29 | $4.59 |
| Resistance Level | $10.25 | $9.53 |
| Average True Range (ATR) | 0.24 | 0.40 |
| MACD | -0.01 | 0.06 |
| Stochastic Oscillator | 43.46 | 18.87 |
Price Performance
Historical ComparisonAbout CRT Cross Timbers Royalty Trust
Cross Timbers Royalty Trust is a United States-based trust. The net profits interests are derived from producing royalty, overriding royalty interests, and working interest properties. The underlying properties of the trust include producing properties in Texas, Oklahoma, and New Mexico.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.